Vilobelimab
Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction. By preventing the activation and chemotaxis of neutrophils and reducing inflammatory signaling, Vilobelimab could benefit researching conditions such as sepsis and COVID-19 .
Product Specifications
CAS Number
2250440-41-4
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog